Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: GLP1-RA Clear all
Completed Phase 1 Interventional

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

NCT05377333
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY3457263, Placebo, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Anniston, Alabama • Anaheim, California • South Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

NCT03987919
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Semaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
51
States / cities
Birmingham, Alabama • Sheffield, Alabama • Huntington Park, California + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting Not applicable Interventional

Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia

NCT06654219
View directory record Official record
Conditions
Pulmonary Aspiration
Interventions
GLP-1 RA users with prolonged fasting instructions, GLP-1 RA users with standard NPO instructions
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Tirzepatide Impact Assessment Study

NCT07740291
View directory record Official record
Conditions
Obesity & Overweight, Cardiometabolic Health Indicators, Addiction, Eating Disorders, Mental Health
Interventions
GLP-1 Receptor Agonist Therapy, Structured Lifestyle Intervention
Drug · Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting Not applicable Interventional

Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity

NCT07091500
View directory record Official record
Conditions
Obesity, Skeletal Muscle, Brain Connectivity
Interventions
Exercise training, Semaglutide, Therapy Cessation
Behavioral · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting Phase 4 Interventional

Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

NCT06774079
View directory record Official record
Conditions
Crohn Disease
Interventions
Tirzepatide, Mediterranean diet
Drug · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Not listed No phase listed Observational

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

NCT05161429
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 26, 2026, 4:24 PM EDT
Active, not recruiting Phase 4 Interventional

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435
View directory record Official record
Conditions
Type 2 Diabetes (T2DM)
Interventions
SGLT-2 inhibitor, GLP1-RA
Drug
Lead sponsor
MaryAnn Banerji
Other
Eligibility
24 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Completed No phase listed Observational

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

NCT05526157
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting Not applicable Interventional

Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

NCT06593314
View directory record Official record
Conditions
Heart Failure, Diabetes
Interventions
Message with EchoGo, Standard Message
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Not listed Not applicable Interventional

Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes

NCT04862858
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Educational Intervention
Other
Lead sponsor
Humana Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
4,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 20, 2022 · Synced Oct 26, 2026, 4:24 PM EDT
Active, not recruiting Phase 2 Interventional

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

NCT06005012
View directory record Official record
Conditions
Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 79 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Enrolling by invitation No phase listed Observational

Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

NCT07713901
View directory record Official record
Conditions
Medullary Thyroid Carcinoma
Interventions
No treatment given
Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
93,600,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Parsippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effects of GLP-1 RAs on Human Lactation Outcomes

NCT07720414
View directory record Official record
Conditions
Lactation, Weight Loss
Interventions
Injected GLP-1 Receptor Agonists and Dual Agonists
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

GLP-1 RA for Stage 1 Type 1 Diabetes

NCT07430332
View directory record Official record
Conditions
Stage 1 Diabetes Mellitus, Type 1
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Not applicable Interventional Results available

Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

NCT02846233
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Phase 2 Interventional Results available

Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease

NCT05254418
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
dulaglutide injection
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Diabetes Remote Intervention to improVe Use of Evidence-based Medications

NCT06046560
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes
Interventions
SGLT2 inhibitor, GLP-1 RA, Education-First
Drug · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
27 Years to 79 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

NCT07502508
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
icovamenib 100 mg, Placebo
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Canoga Park, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Active, not recruiting Not applicable Interventional

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

NCT05040087
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Intensification of diabetes medication based largely on HbA1c levels, Intensification of diabetes medication based on glucose levels
Other
Lead sponsor
Foundation for Atlanta Veterans Education and Research, Inc.
Other
Eligibility
40 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Transformative Research in Diabetic Nephropathy 2.0

NCT07444203
View directory record Official record
Conditions
Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions
Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 26, 2026, 4:24 PM EDT
Completed Phase 4 Interventional Results available

A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)

NCT05706506
View directory record Official record
Conditions
Type 2 Diabetes, Diabetes Mellitus, Type 2
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
32
States / cities
Tempe, Arizona • Corona, California • Gardena, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 26, 2026, 4:24 PM EDT
Completed No phase listed Observational

Gastric Volume in Patients on GLP-1 Medications

NCT05903482
View directory record Official record
Conditions
Diabetes
Interventions
None - observational
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Oct 26, 2026, 4:24 PM EDT